相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N. C. Turner et al.
ANNALS OF ONCOLOGY (2019)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
Marija Balic et al.
BREAST CARE (2019)
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
M. Oliveira et al.
ANNALS OF ONCOLOGY (2019)
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
Sandeep Rajput et al.
Oncotarget (2019)
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
Nicci Owusu-Brackett et al.
Oncotarget (2019)
Occurrence of the potent mutagens 2-nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles
Aldenor G. Santos et al.
SCIENTIFIC REPORTS (2019)
A method of producing genetically manipulated mouse mammary gland
Hiroaki Tagaya et al.
BREAST CANCER RESEARCH (2019)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015)
Fatima Cardoso et al.
BREAST (2018)
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
Dimitrios Zardavas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
CANCER THERAPY PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
Eneda Toska et al.
SCIENCE (2017)
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Alejandra Bruna et al.
CELL (2016)
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Hua Yuan et al.
CLINICAL CANCER RESEARCH (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Kristi McIntyre et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin et al.
CLINICAL CANCER RESEARCH (2012)
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression
Gail T. McDonald et al.
EXPERIMENTAL CELL RESEARCH (2010)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer
Jeffrey J. Wallin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
Wei-Chien Huang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Switching ceyclin D-Cdk4 kinase activity on and off
Stacy W. Blain
CELL CYCLE (2008)
PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival
Lana Bozulic et al.
MOLECULAR CELL (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated
Yusuke Fujiwara et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Design and statistical methods in studies using animal models of development
MFW Festing
ILAR JOURNAL (2006)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
p21-mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress
FB Charrier-Savournin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
O Coqueret
TRENDS IN CELL BIOLOGY (2003)
Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel
S Mabuchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A
A Suzuki et al.
CELL DEATH AND DIFFERENTIATION (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
